WORLD INTELLECTUAL PROPERTY ORGA

ION ION

INTERNATIONAL APPLIA. JON PUBLISHED UNDER THE PATE

COOPERATION TREATY (PCT)

(51) International Patent Classification 7:

C07K 14/47, A61K 38/17, G01N 33/68, A61P 25/28, C12N 5/00, A61K 51/00

(11) International Publication Number:

WO 00/6826

A2

(43) International Publication Date: 16 N

16 November 2000 (16.11.0

(21) International Application Number:

PCT/CA00/00515

(22) International Filing Date:

4 May 2000 (04.05.00)

(30) Priority Data:

60/132,592

5 May 1999 (05.05.99)

US

(71) Applicant (for all designated States except US): NEU-ROCHEM, INC. [CA/CA]; 7220 Frederick-Banting, Suite 100, Montréal, Québec H4S 2A1 (CA).

(72) Inventors; and

- (75) Inventors/Applicants (for US only): CHALIFOUR, Robert [CA/CA]; 332 Place Ladouceur, Ile Bizard, Québec H9C 1T4 (CA). GERVAIS, Francine [CA/CA]; 1003 Bellevue, Ile Bizard, Québec H9C 2X5 (CA). GUPTA, Ajay [CA/CA]; 255 St-Louis, Pointe-Claire, Québec H9R 5L6 (CA).
- (74) Agents: MURPHY, Kevin, P. et al.; Swabey Ogilvy Renault, Suite 1600, 1981 Mcgill College Avenue, Montréal, Québec H3A 2Y3 (CA).


(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, B. BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DN DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, I IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LI LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, P RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, T UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GI GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasic patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Europe: patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, G IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, C CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG)

Published

Without international search report and to be republish upon receipt of that report.

(54) Title: STEREOSELECTIVE ANTIFIBRILLOGENIC PEPTIDES AND PEPTIDOMIMETICS THEREOF

Protein - Protein Interaction: Targetted Sites



(57) Abstract

The present invention relates to antifibrillogenic agents for inhibiting amyloidosis and/or for cytoprotection for the treatment amyloidosis disorders. These agents include peptides, isomers thereof and peptidomimetic compounds thereof. These agents comprise peptide having a sequence identified from the glycosaminoglycan (GAG) binding region and the prot-prot interaction region of the amylo protein. The peptide has at least one [D] amino acid isomer substitution. The invention also relates to the peptide bound to a label for vivo imaging of amyloid deposits.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
ΑÜ	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
ΑZ	Azerbaijan	GB	United Kingdom	MC	Моласо	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
ВJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	us	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
cu	Cuba	KZ	Kazakstan	RO	Romania	•	
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		•
DE	Germany	LI	Liechtenstein	SD -	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		•